Validation of the Retinopathy of Prematurity Activity Scale (ROP‐ActS) using retrospective clinical data
Year: 2020
Type: article
Study design: Observational Study
Abstract: PURPOSE: The International Neonatal Consortium recently published a proposed retinopathy of prematurity (ROP) activity scale intended for use in clinical trials after validation. The aim of this study was to validate the ROP activity scale (ROP-ActS) in a ROP screened cohort with protocol based collected data by evaluating the ability of the ROP-Act scores to predict ROP treatment. In addition, we aimed to evaluate the scale's sensitivity characteristic of disease severity by studying association with gestational age (GA) in comparison with conventionally used ROP stage and zone. METHODS: A cohort of 535 preterm infants with 3324 ROP examinations with an end-point of ROP treatment or end of screening in Gothenburg, Sweden, was included. Median GA was 28.1 weeks, 47.5% were girls, and 74 (13.8%) infants were treated for ROP. The validation was performed by estimating probabilities for ROP treatment, and by applying logistic and linear regression. RESULTS: The original ROP-ActS was overall well-ordered with respect to ability to predict ROP treatment but could be improved by re-ordering score 3 (zone II stage 1) and 5 (zone III stage 3) based on our clinical cohort data. The modified ROP-ActS was superior to ROP stage and zone in the prediction analysis of ROP treatment. Modified ROP-ActS was more strongly related to GA than currently used ROP stage, but not zone. CONCLUSION: In the studied cohort, the modified ROP-ActS could better predict ROP treatment compared to ROP stage and zone. Retinopathy of Prematurity Activity Scale (ROP-ActS) had a superior sensitivity characteristic studied through association to GA than conventionally used ROP stage.
Source: Acta Ophthalmologica
DOI: 10.1111/aos.14532
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,600
Funders: Foundation for the National Institutes of Health, Boston Children's Hospital, Recordati Rare Diseases, Knut och Alice Wallenbergs Stiftelse, Göteborgs Universitet, National Institutes of Health, Intellectual and Developmental Disabilities Research Center, Sahlgrenska Akademin, National Eye Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G1024040356, G3916677169, G5019632937, Boston Intellectual and Developmental Disabilities Research Center, G6471330961, Glucose/lipid metabolism and vessel development in phase I ROP, G8498514485, Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center, Dietary control of angiogenesis in retinopathy models
OpenAlex ID: W3037065692